Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

Fig. 1

CSF levels of p-tau235 across syndromic groups stratified by CSF amyloidosis. a In the Paris cohort, CSF p-tau235 was significantly increased in both dementia Aβ+ and MCI Aβ+ when compared with CU Aβ−, MCI Aβ− and dementia Aβ−. b In the BIODEGMAR cohort, CSF p-tau235 was significantly higher in both dementia Aβ+ and MCI Aβ+ when compared with CU Aβ−, MCI Aβ− and dementia Aβ−. Additionally, CSF p-tau235 was significantly increased in dementia Aβ+ when compared with CU Aβ+. Data information: Boxplots show the median, IQR, and all the participants colour-coded based on the presence (red) or absence (blue) of CSF amyloidosis measured with Lumipulse CSF Aβ Aβ1–42/40. P-values were determined using one-way ANOVA adjusted by age and sex, followed by Bonferroni-corrected post hoc comparison (*P <0.05, **P <0.01, ***P <0.001, ****P <0.0001)

Back to article page